Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADH1A | P07327 | 1/20 | 0.44 |
| ▸ | NADK | O95544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22220015 | 0.93 | RNASEL (0.47) | RNASELPOLB | |
| SCHEMBL22219987 | 0.91 | POLB (0.43) | POLBADH1ANADK | |
| SCHEMBL22219981 | 0.91 | POLB (0.54) | RNASELPOLBADH1ANADK | |
| SCHEMBL22219988 | 0.88 | POLB (0.40) | POLBADH1ANADK | |
| SCHEMBL22219802 | 0.87 | POLB (0.52) | RNASELPOLBADH1ANADK | |
| SCHEMBL22219985 | 0.86 | POLB (0.42) | POLBADH1ANADK | |
| SCHEMBL25582525 | 0.86 | RNASEL (0.57) | RNASELPOLB | |
| SCHEMBL22219796 | 0.84 | POLB (0.42) | POLB | |
| SCHEMBL22219945 | 0.83 | BCHE (0.39) | POLBADH1ANADK | |
| SCHEMBL22349171 | 0.82 | RNASEL (0.44) | RNASELPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | RNASEL 692/4885POLB 32/4885ADH1A 2402/4885 |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | RNASEL 692/4885POLB 32/4885ADH1A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.